Tirzepatide 10mg: deciding whether this dose is the right move

How you reach 10mg, and what the schedule is actually for

The titration path for tirzepatide starts at 2.5mg. That first pen exists entirely to let your body adjust, not to produce weight loss on its own. Most people then step through 5mg and 7.5mg at roughly four-week intervals, which means 10mg is normally where you arrive after three months of careful escalation.

That gradual pace matters for a reason. Tirzepatide slows gastric emptying and acts on appetite-regulating centres in the brain via two separate gut-hormone receptors. Introducing the full effect too quickly tends to amplify nausea and other gastrointestinal side effects. The step-by-step approach keeps those manageable for most people. By the time 10mg is on the table, your prescriber will have a clear sense of how you've responded so far.

You can read a broader overview of how the whole treatment works on our tirzepatide information page, which covers the mechanism and licensed use in more detail. What's specific to 10mg is that it often represents the point where tolerability and efficacy start to balance well, and if you want to understand more about tirzepatide l and what that format involves, our dedicated page goes into the detail you need. Many people find this dose effective enough that they don't feel the need to go higher, though that remains a clinical conversation.

The decision isn't yours to make unilaterally, and it shouldn't be. If you're weighing up whether to start with Mounjaro or tirzepatide and what that distinction actually means in practice, that question is addressed in detail in our dedicated guide. Your prescriber reviews what's happened at your current dose before any change is confirmed. Evidence of your progress (and of how your body has handled treatment) is part of that review.

What the trial data shows at 10mg specifically

The SURMOUNT-1 trial, which randomised 2,539 adults with obesity and no type 2 diabetes, tested tirzepatide at 5mg, 10mg and 15mg over 72 weeks. At the 10mg dose, participants achieved an average body-weight reduction of around 19%, compared with roughly 3% in the placebo group. Those are meaningful, clinically significant numbers, not a rounding error, and not the product of a small or short study.

For context, the 15mg arm produced around 20–21% average reduction, so the gap between 10mg and the maximum dose is smaller than the gap between 10mg and doing nothing. The SURMOUNT-1 paper in the New England Journal of Medicine remains the primary evidence base for these figures. NICE cited this data when recommending tirzepatide in its guidance (TA1026, published December 2024).

These are averages across thousands of participants, and individual results vary. Weight loss in clinical trials is always described as average reduction, alongside a lifestyle programme, a reduced-calorie diet and increased physical activity were part of the trial protocol. Treatment in isolation, without those changes, is not what the trials studied, and it is not what the licence reflects.

There is no guarantee of a specific outcome. But the evidence at 10mg is, by any honest measure, robust.

The dose-increase decision: what tilts it one way or the other

This is the core question for anyone currently at 7.5mg: is 10mg the right next step, or not yet? A few factors go into that.

Tolerability is first. If gastrointestinal symptoms (nausea, loose stools, feeling full very quickly) are still prominent at your current dose, a prescriber may advise staying where you are for another cycle before moving up. Rushing the titration tends to worsen side effects without improving outcomes.

Response is second. If progress has plateaued and tolerability is reasonable, stepping up makes clinical sense. If progress is continuing steadily, there may be no urgency. The prescriber's job is to read that picture.

Evidence is third. For repeat orders and dose increases at nume, your prescriber requires evidence of your current treatment and weight trajectory before confirming a change. That is a patient-safety measure, not a bureaucratic hurdle. Our clinical team reviews every repeat, not a queue, not an algorithm, a named prescriber reads it.

For those wondering about cost at this stage of treatment, context is available on our weight-loss treatment overview. Pricing varies by dose and provider; what a legitimate price always includes is the clinical assessment, prescription and aftercare, not just the pen.

Practical realities of being on tirzepatide 10mg

Tirzepatide is a once-weekly subcutaneous injection. The 10mg KwikPen, like all Mounjaro pens, delivers four weekly doses and is stored in a fridge at 2–8°C. If you want to understand exactly what you receive when you order, our guide to the 10 ml tirzepatide format explains the volume, presentation and what to expect when your pen arrives. For the exact window during which the pen can safely be kept at room temperature (useful for travel or when your fridge access is interrupted) the Mounjaro Patient Information Leaflet is the definitive reference; no content page should substitute for it.

When an order placed with nume before 12pm is clinically approved, it's dispatched the same working day. It arrives via DPD the next working day, in plain, unbranded packaging, tracked to your phone, no indication on the outside of what's inside. For many people that matters.

Injection sites are the abdomen, thigh or upper arm, rotated each week. The NHS patient page on tirzepatide covers injection technique and common side effects in plain language and is worth reading if you're new to self-injecting. The most frequently reported side effects at any dose are gastrointestinal: nausea, constipation, diarrhoea and indigestion are the main ones. They tend to be most noticeable after starting or stepping up, and ease for most people within the first two weeks at a new dose. Get urgent medical advice for severe stomach pain that extends to the back, this can be a sign of pancreatitis, which the MHRA flagged as a known, infrequent but serious risk in its January 2026 Drug Safety Update.

If you'd like to understand how 10mg sits within the broader Mounjaro range, the Mounjaro pillar page maps the full licensed schedule and the clinical pathway in context. For those considering whether a higher supply option such as tirzepatide 30 makes sense for their circumstances, that page covers what's included and how it works. And if you're ready to talk to a prescriber about your own situation, you can check your eligibility with nume at no cost.